pyrroles has been researched along with saroglitazar in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 26 (54.17) | 24.3611 |
| 2020's | 22 (45.83) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, R | 1 |
| Jain, MR; Jani, RH; Kansagra, K; Patel, H | 1 |
| Bhansali, A; Jani, RH; Jariwala, G; Jha, P; Joshi, S; Mukhopadhyay, S; Pai, V | 1 |
| Chatterjee, S; Majumder, A; Ray, S | 1 |
| Joshi, SR | 1 |
| Luthra, A; Misra, A | 1 |
| Deshpande, A; Jani, RH; Joshi, S; Toshniwal, H | 1 |
| Bhatt, C; Dash, R; Ghoghari, A; Gupta, R; Jha, A; Kansagra, K; Patel, H; Singh, K; Srinivas, NR | 1 |
| Lam, S | 1 |
| Kelwade, J; Nagesh, VS; Sethi, BK; Vaseem, A | 1 |
| Bhattacharjee, S; Das, N; Mandala, A; Mukherjee, B; Mukhopadhyay, S; Roy, SS | 1 |
| Gujarathi, SS; Kansagra, KA; Parikh, DP; Parmar, DV; Parmar, KV; Patel, HB; Patel, HV; Patel, JA; Patel, MR; Patil, US; Soni, MM; Srinivas, NR | 1 |
| Cheng, XC; Feng, XY; Jia, WQ; Jing, Z; Liu, JW; Liu, X; Liu, YY; Wang, SQ; Xu, WR | 1 |
| Bhoi, B; Das, N; Giri, SR; Jain, MR; Kadam, S; Karmakar, E; Patel, H; Patel, PR; Ranvir, R; Rath, A; Rathod, R; Roy, SS; Swain, P; Trivedi, C; Wahli, W | 1 |
| Giri, P; Gupta, L; Jain, MR; Modi, N; Patel, H; Patel, P; Patel, U; Shah, K; Singh, S; Srinivas, NR | 1 |
| Gaikwad, AN; Goand, UK; Gupta, A; Gupta, S; Kumar, D; Rajan, S; Shankar, K; Srivastava, A; Srivastava, AK; Varshney, S; Vishwakarma, AL | 1 |
| Joshi, SN; Parmar, DV; Srinivas, NR | 1 |
| Shah, SN | 1 |
| Bhagat, A; Bhosle, D; Bhosle, V; Bobde, J; Kadam, R; Shaikh, H | 1 |
| Balakumar, P; Mahadevan, N; Sambathkumar, R | 1 |
| Abdelsalam, RM; Al-Shorbagy, MY; El-Ansary, MR; Hassan, A; Hassan, NF; Nada, SA | 1 |
| Jaiswal, A; Kaul, U; Manjunath, K; Parmar, D; Parmar, K; Patil, KP; Shah, M | 1 |
| Blackhurst, D; Imperial, E; Kamau, F; Mwangi, P; Salie, R; Strijdom, H | 1 |
| El-Awady, MS; Makled, MN; Sharawy, MH | 1 |
| Bhansali, A; Bhansali, S; Hawkins, M; Jain, N; Kaur, S; Kurpad, AV; Rastogi, A; Sharma, A | 1 |
| Boeckmans, J; Buyl, K; De Kock, J; M Rodrigues, R; Natale, A; Rogiers, V; Rombaut, M; Vanhaecke, T | 1 |
| Chhina, RS; Goyal, O; Goyal, P | 1 |
| Bhatt, J; Dunbar, RL; Parmar, DV; Parmar, K; Rastogi, A; Thacker, HP | 1 |
| El-Kashef, DH; Makled, MN | 1 |
| Alonso, C; Bedossa, P; Bhat, M; Caffrey, R; Giri, SR; Jain, MR; Koduru, SV; Kumar, DP; Marioneaux, J; Philip, B; Santhekadur, PK; Sanyal, AJ | 1 |
| Faldu, K; Krishnappa, M; Maroo, S; Mody, N; Parmar, D; Parmar, K; Patil, K; Shah, C; Trivedi, P | 1 |
| Chhina, RS; Goyal, O; Goyal, P; Kaur, J; Nohria, S; Sharma, S; Sood, A | 1 |
| Arora, S; Bishnoi, M; Chopra, K; Dharavath, RN; Kondepudi, KK | 1 |
| Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, MS; Patel, V; Savsani, H | 1 |
| González-Huezo, MS; Muñoz-Espinosa, LE; Parmar, D; Payan-Olivas, R; Pio Cruz-Lopez, JL; Shaikh, F; Vuppalanchi, R | 1 |
| Awasty, V; Chalasani, N; Cusi, K; Gawrieh, S; Kowdley, KV; Lai, M; Loo, N; Mohseni, R; Noureddin, M; Parmar, D; Patel, P; Schiff, E | 1 |
| Francque, S | 1 |
| Jagdish, RK; Kulkarni, A; Kumar, K | 1 |
| Honda, A; Ishii, I; Kamata, S; Machida, Y; Nemoto, A; Oyama, T; Satta, C; Terasawa, K; Uchii, K | 1 |
| Bainbridge, JD; Caldwell, SH; Chalasani, NP; deLemos, AS; Goldberg, DS; Levy, C; Mena, EA; Parmar, DV; Pyrsopoulos, N; Ravinuthala, R; Rossi, S; Shaikh, F; Sheikh, A; Vuppalanchi, R | 1 |
| Afarin, R; Akbari, R; Behdarvand, T; Jalali, MT; Mohammadtaghvaei, N; Yaghooti, H | 1 |
| Eqbal, F; Rehman, H; Shuja, SH | 1 |
| Dikshit, M; Gupta, SK; Jatavallabhula, SL; Kamboj, P; Kumar, A; Kumar, Y; Kumari, D; Mahajan, D; Mukhi, S; Rai, RK; Sarkar, S; Sasibhushan, V; Sharma, V | 1 |
| Cruz-López, P; González, JG; Parmar, D; Rodriguez-Gutierrez, R; Shaikh, F | 1 |
| Alarifi, S; Gautam, N; Mohseen, M; Pal, AK; Palanivel, H; Prabhu, SV; Saxena, M | 1 |
| Adela, R; Durga, DR; Mounika, N; Mudimala, P | 1 |
| Dutta, D; Misra, A; Mohindra, R | 1 |
| Hayes, H; Lawitz, E; Momin, T; Parmar, D; Patel, H; Shaikh, F; Swint, K | 1 |
6 review(s) available for pyrroles and saroglitazar
| Article | Year |
|---|---|
Saroglitazar for the treatment of dyslipidemia in diabetic patients.
Topics: Animals; Atherosclerosis; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Glycated Hemoglobin; Humans; Lipids; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Risk Factors | 2015 |
A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia.
Topics: Diabetes Mellitus, Type 2; Disease Management; Dyslipidemias; Humans; Insulin Resistance; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles | 2019 |
New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; India; Lipids; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Signal Transduction; Time Factors; Treatment Outcome | 2019 |
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Topics: Chalcones; Diabetes Mellitus, Type 2; Drug Development; Fatty Liver; Humans; Hypoglycemic Agents; Inflammation; Liver; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Pioglitazone; Propionates; Pyrroles | 2019 |
Response to Comment on: "Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".
Topics: Cardiovascular Diseases; Humans; Phenylpropionates; Pyrroles; Randomized Controlled Trials as Topic | 2023 |
Comment on: "Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials".
Topics: Cardiovascular Diseases; Humans; Phenylpropionates; Pyrroles; Randomized Controlled Trials as Topic | 2023 |
12 trial(s) available for pyrroles and saroglitazar
| Article | Year |
|---|---|
Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.
Topics: Adolescent; Adult; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Phenylpropionates; Placebos; PPAR alpha; Pyrroles; Sex Factors; Young Adult | 2013 |
A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRES
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Patient Safety; Phenylpropionates; Prospective Studies; Pyrroles; Risk Reduction Behavior; Treatment Failure; Treatment Outcome; Triglycerides | 2014 |
A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy.
Topics: Adolescent; Adult; Aged; Cholesterol; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hypertriglyceridemia; Insulin; Lipoproteins; Male; Middle Aged; Phenylpropionates; Prospective Studies; Pyrroles | 2016 |
Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.
Topics: Adult; Area Under Curve; Biological Availability; Cholesterol, HDL; Cross-Over Studies; Energy Intake; Female; Food-Drug Interactions; Humans; Male; Phenylpropionates; PPAR alpha; Pyrroles; Tablets; Therapeutic Equivalency; Young Adult | 2018 |
Limited Sampling Strategy for Accurate Prediction of Pharmacokinetics of Saroglitazar: A 3-point Linear Regression Model Development and Successful Prediction of Human Exposure.
Topics: Adult; Area Under Curve; Cross-Over Studies; Humans; Linear Models; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Pyrroles | 2018 |
Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.
Topics: Dyslipidemias; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Phenylpropionates; Prediabetic State; Prospective Studies; Pyrroles; Triglycerides | 2018 |
Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Endpoint Determination; Female; Glycated Hemoglobin; Humans; Hypertriglyceridemia; Insulin Resistance; Lipids; Male; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles | 2019 |
Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Phenylpropionates; Placebos; Postprandial Period; PPAR alpha; PPAR gamma; Pyrroles; Triglycerides | 2020 |
Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
Topics: Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Lipids; Phenylpropionates; Pioglitazone; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2020 |
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Topics: Adipose Tissue; Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Elasticity Imaging Techniques; Female; gamma-Glutamyltransferase; Humans; Insulin Resistance; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Triglycerides | 2021 |
Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.
Topics: Double-Blind Method; Female; Humans; Liver Cirrhosis, Biliary; Male; Middle Aged; Phenylpropionates; Placebos; Pyrroles; Treatment Outcome | 2022 |
Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial.
Topics: Adult; Double-Blind Method; Fenofibrate; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Phenylpropionates; Pyrroles; Triglycerides | 2022 |
30 other study(ies) available for pyrroles and saroglitazar
| Article | Year |
|---|---|
The first approved agent in the Glitazar's Class: Saroglitazar.
Topics: Administration, Oral; Adult; Clinical Trials, Phase IV as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypoglycemic Agents; India; Lipid Metabolism; Middle Aged; Phenylpropionates; Pyrroles; Young Adult | 2014 |
Observational study of effects of Saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Male; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Treatment Outcome; Triglycerides | 2015 |
The marketing of unproven drugs for diabetes and dyslipidaemia in India.
Topics: Berberine; Diabetes Mellitus, Type 2; Drug Approval; Drug Industry; Dyslipidemias; Humans; Hydroxychloroquine; Hypoglycemic Agents; India; Marketing; Phenylpropionates; Pyrroles | 2015 |
Quantitative determination of saroglitazar, a predominantly PPAR alpha agonist, in human plasma by a LC-MS/MS method utilizing electrospray ionization in a positive mode.
Topics: Calibration; Chromatography, Liquid; Humans; Limit of Detection; Phenylpropionates; PPAR alpha; Pyrroles; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2016 |
American Diabetes Association - 76th Scientific Sessions (June 10-14, 2016 - New Orleans, Louisiana, USA).
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Phenylpropionates; Pyrroles | 2016 |
Unique Interaction of Saroglitazar with Insulin.
Topics: Blood Glucose; Diabetes Mellitus; Drug Interactions; Female; Humans; Hypertriglyceridemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Middle Aged; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles | 2015 |
Thioredoxin interacting protein mediates lipid-induced impairment of glucose uptake in skeletal muscle.
Topics: AMP-Activated Protein Kinases; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biological Transport, Active; Carrier Proteins; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Fenofibrate; Glucose; Glucose Transporter Type 4; Insulin Resistance; Mice; Muscle Fibers, Skeletal; Nuclear Proteins; Palmitic Acid; Phenylpropionates; Pyrroles; Reactive Oxygen Species; Sirtuin 1; Thioredoxins; Transcription Factors | 2016 |
Virtual identification of novel PPARα/γ dual agonists by scaffold hopping of saroglitazar.
Topics: Diabetes Mellitus; Drug Discovery; Dyslipidemias; Humans; Hypoglycemic Agents; Molecular Docking Simulation; Molecular Dynamics Simulation; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles | 2018 |
Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Biomarkers; Diet, High-Fat; Fenofibrate; Hep G2 Cells; Humans; Kupffer Cells; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pioglitazone; PPAR alpha; Pyrroles; Tumor Necrosis Factor-alpha | 2018 |
Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.
Topics: Animals; Caco-2 Cells; Dogs; Drug Evaluation, Preclinical; Dyslipidemias; Humans; Mice; Microsomes, Liver; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Rats | 2018 |
Saroglitazar reduces obesity and associated inflammatory consequences in murine adipose tissue.
Topics: Adipose Tissue; Animals; Energy Metabolism; Glucose; Homeostasis; Hypertrophy; Inflammation; Male; Mice; Mice, Inbred C57BL; Obesity; Organ Specificity; Phenylpropionates; Pyrroles | 2018 |
The Road to Preventing Diabetes: Addressing Prediabetes and Concomitant Dyslipidemia.
Topics: Diabetes Mellitus; Dyslipidemias; Humans; Phenylpropionates; Prediabetic State; Pyrroles | 2018 |
Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis.
Topics: Adipocytes; Animals; Down-Regulation; Lipopolysaccharides; Liver; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pyrroles; Rats; Signal Transduction; Toll-Like Receptor 4 | 2019 |
Antiretroviral drug-induced endothelial dysfunction is improved by dual PPARα/γ stimulation in obesity.
Topics: Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Aorta, Thoracic; Disease Models, Animal; Endothelium, Vascular; Male; NADPH Oxidases; Nitric Oxide Synthase Type III; Obesity; Phenylpropionates; PPAR alpha; PPAR gamma; Proto-Oncogene Proteins c-akt; Pyrroles; Rats, Wistar; Signal Transduction; Vasodilation | 2019 |
The dual PPAR-α/γ agonist saroglitazar ameliorates thioacetamide-induced liver fibrosis in rats through regulating leptin.
Topics: Actins; Animals; Becaplermin; Leptin; Liver; Liver Cirrhosis; Male; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Rats, Sprague-Dawley; Thioacetamide; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1 | 2019 |
Saroglitazar Improves Transaminases and Elastography in Patients with Diabetic Dyslipidemia and Non-Alcoholic Fatty Liver Disease.
Topics: Diabetes Mellitus; Dyslipidemias; Elasticity Imaging Techniques; Humans; Liver; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pyrroles; Transaminases | 2020 |
Saroglitazar attenuates renal fibrosis induced by unilateral ureteral obstruction via inhibiting TGF-β/Smad signaling pathway.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Fibrosis; Inflammation; Kidney Diseases; Male; Oxidative Stress; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta1; Ureteral Obstruction | 2020 |
The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Endoplasmic Reticulum Stress; Gene Expression Profiling; Insulin Resistance; Liver; Liver Cirrhosis; Metabolomics; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Signal Transduction | 2020 |
Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Prospective Studies; Pyrroles; Regression Analysis | 2020 |
Saroglitazar, a novel dual PPAR-α/γ agonist, reverses high fat-low protein diet-induced metabolic and cognitive aberrations in C57BL/6J male mice.
Topics: Animals; Cognitive Dysfunction; Diet, High-Fat; Diet, Protein-Restricted; Male; Metabolic Diseases; Mice; Mice, Inbred C57BL; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles | 2021 |
Effect of dual PPAR-α/γ agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy.
Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Chick Embryo; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Female; Hyperoxia; Intercellular Adhesion Molecule-1; Male; Neovascularization, Physiologic; Oxidative Stress; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Rats, Sprague-Dawley; Receptors, Vascular Endothelial Growth Factor; Retina; Retinal Neovascularization; Retinal Vessels; Signal Transduction; Streptozocin; Transcription Factor RelA | 2021 |
A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Female; Humans; Intention to Treat Analysis; Liver Cirrhosis, Biliary; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Pyrroles | 2021 |
Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On!
Topics: Humans; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Pyrroles | 2021 |
Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH.
Topics: Humans; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pyrroles | 2021 |
Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
Topics: Binding Sites; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypolipidemic Agents; Lipid Metabolism; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Protein Domains; Pyrroles; Recombinant Proteins | 2021 |
Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cytokines; Disease Models, Animal; Gene Expression Regulation; Liver; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Rats, Wistar | 2021 |
Saroglitazar - A Potential Therapeutic Option in Treating NASH? [Letter].
Topics: Humans; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pyrroles | 2021 |
Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids.
Topics: Animals; Cell Line; Diet; Diet, High-Fat; Fatty Liver; Fructose; Humans; Hypolipidemic Agents; Insulin Resistance; Lipid Metabolism; Lipidomics; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Phenylpropionates; Pyrroles | 2021 |
Antidiabetic Effect of
Topics: Adipocytes; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Down-Regulation; Gene Expression; Glucose; Hypoglycemic Agents; Inflammation; Lipoproteins, LDL; Momordica charantia; Phenylpropionates; Plant Extracts; Pyrroles; Tamarindus | 2022 |
Pharmacokinetics and Safety Evaluation of Single-Dose Saroglitazar Magnesium in Subjects with Hepatic Impairment.
Topics: Area Under Curve; Humans; Liver Diseases; Phenylpropionates; Pyrroles | 2023 |